OBJECTIVES::  To evaluate the efficacy and safety of interferon-free (IFN-free) therapies for chronic hepatitis C (HCV) patients coinfected with HIV since the possibility to present more adverse effects (AE) in this group of patients, thus increasing the clinical evidence of these therapies. METHODS::  A systematic review was carried out including randomized clinical trials that brought information about efficacy (sustained virologic response, rapid virologic response and virological failure) and safety (adverse events- AE) outcomes. RESULTS::  A total of 10 clinical trials with 1,626 patients were included, mostly with HCV genotype 1 and treated during 12 or 24 weeks. The virological response outcomes evaluated presented rates of approximately 91%, while the rate of virological failure was less than 7%. Discontinuations due to AE were less than 3%. Direct-acting antivirals (DAAs) of second-generation had several advantages: virological response values higher than the mean reached by older therapies based on the use of IFN, reduced treatment time, increased safety and the possibility of several combinations to suit the patient's need. CONCLUSIONS::  In this way, IFN-free therapies appear as a good option for the treatment of chronic hepatitis C in the group of patients coinfected with HIV.